MétaCan
Menu
Back to cohort
Record W2794636105 · doi:10.1161/circresaha.117.312579

Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research

2018· review· en· W2794636105 on OpenAlexaff
Steeve Provencher, Stephen L. Archer, F. Daniel Ramirez, Benjamin Hibbert, Roxane Paulin, Olivier Boucherat, Yves Lacasse, Sébastien Bonnet

Bibliographic record

VenueCirculation Research · 2018
Typereview
Languageen
FieldMedicine
TopicPulmonary Hypertension Research and Treatments
Canadian institutionsInstitut universitaire de cardiologie et de pneumologie de QuébecQueen's UniversityUniversity of Ottawa
FundersActelion PharmaceuticalsNational Heart, Lung, and Blood InstituteNational Institutes of Health
KeywordsMedicineClinical trialIntensive care medicineTranslational researchPreclinical testingRigourPulmonary hypertensionPreclinical researchClinical study designResearch designRandomized controlled trialDrug developmentTreprostinilMedical physicsPathologyInternal medicineDrugPharmacology

Abstract

fetched live from OpenAlex

Despite advances in our understanding of the pathophysiology and the management of pulmonary arterial hypertension (PAH), significant therapeutic gaps remain for this devastating disease. Yet, few innovative therapies beyond the traditional pathways of endothelial dysfunction have reached clinical trial phases in PAH. Although there are inherent limitations of the currently available models of PAH, the leaky pipeline of innovative therapies relates, in part, to flawed preclinical research methodology, including lack of rigour in trial design, incomplete invasive hemodynamic assessment, and lack of careful translational studies that replicate randomized controlled trials in humans with attention to adverse effects and benefits. Rigorous methodology should include the use of prespecified eligibility criteria, sample sizes that permit valid statistical analysis, randomization, blinded assessment of standardized outcomes, and transparent reporting of results. Better design and implementation of preclinical studies can minimize inherent flaws in the models of PAH, reduce the risk of bias, and enhance external validity and our ability to distinguish truly promising therapies form many false-positive or overstated leads. Ideally, preclinical studies should use advanced imaging, study several preclinical pulmonary hypertension models, or correlate rodent and human findings and consider the fate of the right ventricle, which is the major determinant of prognosis in human PAH. Although these principles are widely endorsed, empirical evidence suggests that such rigor is often lacking in pulmonary hypertension preclinical research. The present article discusses the pitfalls in the design of preclinical pulmonary hypertension trials and discusses opportunities to create preclinical trials with improved predictive value in guiding early-phase drug development in patients with PAH, which will need support not only from researchers, peer reviewers, and editors but also from academic institutions, funding agencies, and animal ethics authorities.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.835
metaresearch head score (Gemma)0.905
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.165
Threshold uncertainty score0.204

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.8350.905
Meta-epidemiology (narrow)0.0040.004
Meta-epidemiology (broad)0.0090.010
Bibliometrics0.0180.016
Science and technology studies0.0070.032
Scholarly communication0.0200.010
Open science0.0130.016
Research integrity0.0160.018
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.664
GPT teacher head0.596
Teacher spread0.068 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designSystematic review
DomainMethods
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations149
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueCirculation ResearchSame topicPulmonary Hypertension Research and TreatmentsFrench-language works237,207